| Indication |
Apixaban |
Dabigatran |
Edoxaban |
Rivaroxaban |
| VTE prevention after major orthopaedic surgery* |
||||
| Hip |
2.5 mg bid |
220 mg od |
O |
10 mg od |
| Knee |
2.5 mg bid |
220 mg od |
O |
10 mg od |
| VTE treatment† |
||||
| DVT |
10 mg bid for 7 days and 5 mg bid thereafter |
150 mg bid, following treatment with a parenteral anticoagulant for ≥5 days |
60 mg od, following treatment with a parenteral anticoagulant for ≥5 days |
15 mg bid for 21 days and 20 mg od thereafter |
| PE |
||||
| VTE secondary prevention |
2.5 mg bid |
|||
| Stroke prevention in patients with AF‡ |
5 mg bid |
150 mg bid |
60 mg od |
20 mg od |
| Acute coronary syndrome§ |
O |
O |
O |
2.5 mg bid |